Use of ASC and ASC-CM to treat ARDS, SARS, and MERS
Disclosed herein is that the systemic administration of ASC conditioned media diminished LPS-induced lung injury by inhibiting epithelial permeability, neutrophil inflammatory response, and secretion of pro-inflammatory TNFα. It is also shown that ARDS lung is able to retain IV-delivered ASC for a substantial amount of time, with no evidence of the significant cell distribution to other organs at this time point. These findings provide optimization of cell-based and cell-free therapy for the treatment of ARDS, including occurrences of ARDS caused by upper respiratory tract infections such as SARS and MERS.
1. A method for treating a patient, comprising the step of:
administering to a patient at least one therapeutically effective dose of an agent comprising adipose-derived Adult Stem Cell-Conditioned Media, wherein the adipose-derived Adult Stem Cell-Conditioned Media is derived from adipose-derived Adult Stem Cells that are negative for CD31 and CD45,
wherein the patient is afflicted with Adult Respiratory Distress Syndrome caused by inflammation and barrier hyperpermeability, and wherein the patient is selected from the group consisting of: human and animal.
2. The method according to claim 1 , wherein the Adult Respiratory Distress Syndrome is caused by an upper respiratory tract infection caused by at least one coronavirus selected from the group consisting of: Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus.
3. The method according to claim 1 , where the therapeutically effective dose of the agent is administered intravenously.
4. The method according to claim 1 , wherein the patient is administered a therapeutically effective dose of the adipose-derived Adult Stem Cell-Conditioned Media, the adipose-derived Adult Stem Cell-Conditioned Media comprising material have a molecular weight of greater than about 10,000 Daltons.
5. The method according to claim 4 , wherein the adipose-derived Adult Stem Cell-Conditioned Media is administered intravenously.
6. The method according to claim 4 , wherein the adipose-derived Adult Stem Cell-Conditioned Media is administered by aspirating the material into at least one lung of the patient.
7. The method according to claim 5 , wherein the dose of the adipose-derived Adult Stem Cell-Conditioned Media administered intravenously is about 0.1ml/kg to about 2.0 ml/kg, of 100× concentrate of the adipose-derived Adult Stem Cell-Conditioned Media.
8. The method according to claim 5 , wherein the dose of the adipose-derived Adult Stem Cell-Conditioned Media administered intravenously is about 0.5ml/kg to about 1.0 ml/kg, of 100× concentrate of the adipose-derived Adult Stem Cell-Conditioned Media.
9. The method according to claim 4 , further comprising the step of formulating the adipose-derived Adult Stem Cell-Conditioned Media material to avoid heat sensitivity.
10. The method according to claim 4 , further comprising the step of formulating the adipose-derived Adult Stem Cell-Conditioned Media material to avoid exosome sensitivity.
11. The method according to claim 1 , wherein the patient is administered a therapeutically effective dose of the adipose-derived Adult Stem Cell-Conditioned Media, the adipose-derived Adult Stem Cell-Conditioned Media comprising material have a molecular weight of greater than about 50,000 Daltons.
12. The method according to claim 1 , wherein the patient is administered a therapeutically effective dose of the adipose-derived Adult Stem Cell-Conditioned Media, the adipose-derived Adult Stem Cell-Conditioned Media comprising material have a molecular weight of greater than about 60,000 Daltons.
13. The method according to claim 1 , wherein the patient is administered a therapeutically effective dose of the adipose-derived Adult Stem Cell-Conditioned Media, the adipose-derived Adult Stem Cell-Conditioned Media comprising material have a molecular weight of greater than about 70,000 Daltons.
14. The method according to claim 1 , wherein the patient is administered a therapeutically effective dose of the adipose-derived Adult Stem Cell-Conditioned Media, the adipose-derived Adult Stem Cell-Conditioned Media comprising material have a molecular weight of greater than about 80,000 Daltons.
15. The method according to claim 1 , wherein the patient is administered a therapeutically effective dose of the adipose-derived Adult Stem Cell-Conditioned Media, the adipose-derived Adult Stem Cell-Conditioned Media comprising material have a molecular weight of greater than about 100,000 Daltons.
16. The method according to claim 1 , wherein the patient is administered a therapeutically effective dose of the adipose-derived Adult Stem Cell-Conditioned Media, the adipose-derived Adult Stem Cell-Conditioned Media comprising material have a molecular weight of greater than about 150,000 Daltons.
17. The method according to claim 1 , wherein the patient is administered a therapeutically effective dose of a fraction of the adipose-derived Adult Stem Cell-Conditioned Media, comprised of exosomes.
18. The method according to claim 1 , wherein the patient is administered a therapeutically effective dose of a fraction of the adipose-derived Adult Stem Cell-Conditioned Media, comprised of exosomes concentrated by any of filtration, centrifugation, or precipitation and resuspension.
19. The method according to claim 1 , wherein the inflammation and barrier hyperpermeability are induced by gram-negative bacterial infection or endotoxin.
20. A method of suppressing inflammation and barrier hyperpermeability, comprising providing a subject at least one therapeutically effective dose of an agent comprising adipose-derived Adult Stem Cell-Conditioned Media, wherein the adipose-derived Adult Stem Cell-Conditioned Media is adipose-derived Adult Stem Cell-Conditioned Media derived from adipose-derived Adult Stem Cells that are negative for CD31 and CD45.
21. The method according to claim 20 , wherein the subject comprises a human, an animal, a cell, or a tissue.